Eton Pharmaceuticals, Inc. Forecast, price target & analysts
Eton Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation
Eton Pharmaceuticals, Inc. Classifications & Recommendation
Eton Pharmaceuticals, Inc. Price Target
| Target Price | $70.38 |
| Price | $55.36 |
| Potential |
27.13%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Eton Pharmaceuticals, Inc. 2027 .
The average Eton Pharmaceuticals, Inc. target price is $70.38.
This is
27.13%
register free of charge
$73.50
32.77%
register free of charge
$62.62
13.11%
register free of charge
|
|
| A rating was issued by 10 analysts: 9 Analysts recommend Eton Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Eton Pharmaceuticals, Inc. stock has an average upside potential 2027 of
27.13%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 79.95 | 145.70 |
| 104.95% | 82.24% | |
| EBITDA Margin | 4.73% | 37.73% |
| 277.34% | 698.02% | |
| Net Margin | -5.75% | 23.37% |
| 41.24% | 506.18% |
6 Analysts have issued a sales forecast Eton Pharmaceuticals, Inc. 2026 . The average Eton Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Eton Pharmaceuticals, Inc. EBITDA forecast 2026. The average Eton Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Eton Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average Eton Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.17 | 1.20 |
| 13.33% | 805.88% | |
| P/E | 46.00 | |
| EV/Sales | 10.87 |
6 Analysts have issued a Eton Pharmaceuticals, Inc. forecast for earnings per share. The average Eton Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Eton Pharmaceuticals, Inc....
Current Eton Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 11 2026 |
| Craig-Hallum |
Locked
➜
Locked
|
Locked | Jul 28 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jul 17 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 15 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 11 2026 |
|
Locked
Craig-Hallum:
Locked
➜
Locked
|
Jul 28 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jul 17 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 15 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
